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KEY POINTS 
 
 Autocrine FGF signaling protects MM cells from oxidative stress-induced apoptosis via c-
Myc oncoprotein stabilization 
 
 FGF blockade induces apoptosis of MM cells from drug-naive and relapsed/refractory 
patients, representing a novel therapeutic approach in MM 
 
ABSTRACT 
Multiple myeloma (MM), the second most common hematological malignancy, frequently relapses 
because of chemotherapeutic resistance. Fibroblast growth factors (FGFs) act as pro-angiogenic and 
mitogenic cytokines in MM. Here, we demonstrate that the autocrine FGF/FGFR axis is essential 
for MM cell survival and progression by protecting MM cells from oxidative stress-induced 
apoptosis. In keeping with the hypothesis that the intracellular redox status can be a target for 
cancer therapy, we show that extracellular FGF blockade by a FGF blocking approach based on a 
pan-FGF trap small molecule (NSC12) impairs the growth and dissemination of MM cells 
harbouring or not the t(4;14) translocation. NSC12 induces mitochondrial oxidative stress, DNA 
damage and apoptotic cell death in MM cells, prevented by the antioxidant vitamin E or 
mitochondrial catalase overexpression. Mitochondrial oxidative stress occurs as a consequence of 
proteasomal degradation of the c-Myc oncoprotein that leads to glutathione depletion. Accordingly, 
expression of a proteasome-non-degradable c-Myc protein mutant was sufficient to rescue the pro-
apoptotic effects due to FGF blockade. These findings were confirmed on Bortezomib-resistant 
MM cells as well as on bone marrow-derived primary MM cells from newly diagnosed and 
relapsed/refractory patients, including plasma cells bearing the t(4;14) translocation obtained from 
high-risk MM patients. Altogether, our findings dissect for the first time the mechanism by which 
the FGF/FGFR system plays a non-redundant role in MM cell survival and disease progression, and 
indicate that FGF targeting may represent a therapeutic approach for MM patients with poor 
prognosis and advanced disease stage.  
 
KEYWORDS  
Multiple myeloma, FGF/FGFR system, FGF trap, FGF inhibition, mitochondrial oxidative stress, c-
Myc, proteasome 
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INTRODUCTION 
Multiple myeloma (MM) represents the second most common hematological malignancy
1
 and is 
characterized by the clonal proliferation of malignant plasma cells within the bone marrow (BM).
2
 
MM relapses in the majority of patients because of chemotherapeutic resistance, indicating that 
novel biologically-based treatments are urgently required.  
MM cells behavior is determined by their genetic background and cross-talk with the BM 
microenvironment which activates a pleiotropic cascade of proliferative/anti-apoptotic signaling 
pathways.
3,4
 These events are triggered by the production of several growth factors by BM stromal 
cells (BMSCs) and/or MM cells in a paracrine/autocrine manner, leading to disease progression and 
drug resistance. In this frame, fibroblast growth factors (FGFs) play a pivotal role acting as potent 
pro-angiogenic mediators
5-8
 and mitogenic cytokines.
9-11
 Elevated levels of FGF2 are detectable in 
the BM and serum of MM patients and correlate with disease activity.
12-14
 In addition, patient-
derived MM cells secrete FGF2, representing the prevailing source in the BM of patients with 
active disease.
8,9
  
The relevance of autocrine/paracrine FGF signaling in MM is supported by the observation that 
FGF receptors (FGFRs) are expressed by MM cell lines, patient-derived MM cells and within the 
BM milieu.
9,11,15
 Also, FGFR3 has been implicated in MM cell proliferation and survival 
16-20
 and 
15% of MM patients overexpress FGFR3 due to a t(4;14)(p16.3;q32) translocation.
21
 Although a 
small fraction of these patients harbor a FGFR3 activating mutation, the majority of them 
upregulate the wild-type FGFR3 receptor, thus depending on FGF ligand for activation.
22
 MM cells 
express various FGFs, including FGF2, regardless of FGFR3 up-regulation,
11,23
 suggesting that 
autocrine FGF signaling may contribute to MM growth also independently from deregulated FGFR 
expression.  
Altogether these findings make the FGF/FGFR system a promising target in MM therapy, and FGF 
inhibitors may exert a simultaneous “two compartment” effect by hampering autocrine/paracrine 
oncogenic signaling in MM.
24
  
Recently, we have identified the PTX3-derived small molecule NSC12 as the first orally active pan-
FGF trap able to inhibit FGFR activation and tumor growth in various FGF-dependent murine and 
human cancer models.
25,26
 Notably, extracellular FGF traps, including NSC12, appear to be devoid 
of the toxicities associated to tyrosine kinase (TK) FGFR inhibitors, 
26,27
 thus representing a 
potential alternative to inhibit the FGF/FGFR system in MM.  
Here, we dissected for the first time the mechanism by which the FGF/FGFR system plays a non-
redundant role in MM cell survival and disease progression. Our findings reveal that FGF blockade 
by NSC12 triggers MM mitochondrial oxidative stress, DNA damage and apoptotic cell death via 
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the proteasomal degradation of the c-Myc oncoprotein. Our findings point to the FGF trapping 
approach as a promising therapeutic strategy for MM. 
 
MATERIALS AND METHODS 
 
Cell cultures and reagents. KMS-11 and KMS-11/BTZ cells were obtained from the Japanese 
Collection of Research Bioresources (JCRB, Osaka, Japan) cell bank; RPMI8226, U-266, OPM-2 
cells from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, 
Germany); MM.1S cells from ATCC (Manassas, VA, USA); GFP/Luciferase–expressing MM.1S 
cells were from Dr. Ghobrial, (Dana-Farber Cancer Institute, Boston, MA). All cell lines were 
maintained at low passage in RPMI1640 medium supplemented with 10% heat inactivated FBS and 
2.0 mM glutamine, tested regularly for Mycoplasma negativity, and authenticated by PowerPlex 
Fusion System (Promega, Madison, USA).  
For lentiviral transduction of KMS-11 cells, particles coding for the mitochondrial Catalase (pLVX-
EF1a-IRES-puro-CatalaseMito),
28
 the cytoplasmic Catalase (pLVX-IRES-neo-hCatalaseCito),
28
 or 
the mutated Myc (Lenti-Myc T58A, Gentaur s.r.l, Bergamo, Italy) were used. 
For details about the reagents used, see the reagent table in Supplemental Information.  
 
Cytofluorimetric analyses. Cytofluorimetric analyses were performed using the MACSQuant 
Analyzer (Miltenyi Biotec). Viable cell counting and cell cycle analyses were performed as 
described.
26
 Mitochondrial membrane depolarization, mitochondrial (mt)ROS production and GSH 
levels were determined using the fluorescent probes tetramethylrhodamine ethyl ester (TMRE), 
Mitosox and ThiolTracker Violet (Thermo Fischer Scientific), respectively. Apoptotic cell death 
was assessed by Annexin-V/Iodide Propidium double staining (Immunostep) according to 
manufacturer’s instructions.  
 
Western blot analysis. Cells were washed in cold PBS and homogenized in NP-40 lysis buffer (1% 
NP-40, 20 mM Tris–HCl pH 8, 137 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM sodium 
orthovanadate, 10 g/mL aprotinin, 10 g/mL leupeptin). Protein concentration in the supernatants 
was determined using the Bradford protein assay (Bio-Rad Laboratories). Activation of signaling 
pathways and expression of specific proteins were detected using specific antibodies indicated in 
the reagent table in Supplemental Information.  
For murine bone marrow analysis, femurs were explanted from mice systemically injected with 
GFP/Luciferase expressing MM.1S cells, flushed using PBS, and cells collected and processed as 
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indicated above. -actin, -tubulin or GAPDH were used as loading controls (see reagent table in 
Supplemental Information for antibodies details). Chemiluminescent signal was acquired by 
ChemiDoc™ Imaging System (BioRad) and analyzed using the ImageJ software 
(http://rsb.info.nih.gov/ij/).   
 
Human phospho-protein proteome profiler array. Lysates (200 g) from DMSO and NSC12-
treated cells were incubated with the human phospho-kinase array kit (R&D Systems) according to 
manufacturer’s instructions. Chemiluminescent signal was acquired and analyzed using the ImageJ 
software.   
 
Genome-wide expression profiling (GEP). GEP was performed on cells treated with NSC12 (6 
µM) for 6 or 12 hours, as reported in Supplemental Information. A cut-off of p-value < 0.01 (FDR 
corrected) and Log2 fold change ± 2 was applied to select differentially expressed genes.  
 
RT-PCR and RT-qPCR. Total RNA was extracted using TRIzol Reagent (Invitrogen) according 
to manufacturer’s instructions. Two µg of total RNA were retro-transcribed with MMLV reverse 
transcriptase (Invitrogen) using random hexaprimers. Then, cDNA was analysed by 
semiquantitative or quantitative PCR using primers indicated in the reagent table in Supplemental 
Information.  
 
Seahorse analysis. KMS-11 cells were seeded at 4x10
5
 cells/well on Seahorse XFe24 culture plates 
(Agilent) previously treated with 3.5 µg/cm
2
 Corning™ Cell-Tak Cell and Tissue Adhesive. 
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) measurements were 
performed using a Seahorse XFe24 Extracellular Flux Analyzer (XFe Wave software). For further 
details see Supplemental Information. 
 
Subcutaneous human xenografts. Experiments were performed according to the Italian laws (D.L. 
116/92 and following additions) that enforce the EU 86/109 Directive and were approved by the 
Institutional Ethical Committee for Animal Experimentation. 
Six- to eight-week old female NOD/SCID mice (Envigo, Udine, Italy) were injected 
subcutaneously (s.c.) with KMS-11 and RPMI8226 cells (5x10
6 cells/mouse) in 200 µl of PBS. 
When tumors were palpable, mice were randomly assigned to receive daily treatment with NSC12 
(7.5 mg/kg) or control/vehicle DMSO. For further details see Supplemental Information.   
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Systemic human xenograft. Six- to eight-week old female SCID Beige mice (Envigo) were 
injected intravenously (i.v) with GFP/Luciferase expressing MM.1S cells (2x10
6
 cells/mouse) in 
100 µl of PBS. Mice were randomly assigned to receive short- or long-term i.p. treatments with 
NSC12 (7.5 mg/kg) or control/vehicle DMSO. For further details see Supplemental Information.  
 
Cytological and histological analyses. Cytospin from patient-derived MM cells were prepared 
using about 2x10
5
 cells/slide. Tumor samples were either embedded in OCT compound and 
immediately frozen or fixed in formalin and embedded in paraffin. All samples were further 
processed as reported in Supplemental Information. 
 
Zebrafish embryo homing model. The model was used as described.
29
 Briefly, MM.1S cells were 
exposed for 3 hours to NSC12 3 M or DMSO. Thirty minutes before the end of treatment, 
CMTPX or CMF2HC  CellTracker dyes (Thermo Fisher Scientific) were added to cell 
suspensions to obtain fluorescently labelled red (NSC12-treated) or blue (DMSO-treated) MM.1S 
cells, respectively. After staining, NSC12- and DMSO-treated cells were washed, mixed together at 
a 1:1 ratio, and co-injected in the bloodstream of zebrafish embryos by the duct of Cuvier. 
Zebrafish experiments were performed as approved by the Institutional Ethical Committee for 
Animal Experimentation. For further details see Supplemental Information.  
 
Patient-derived MM cells. This study was approved by the Institutional Review Board at 
Humanitas Cancer Center of Rozzano (Milan). Informed consent was obtained from all patients. 
Primary CD138
+
 cells were obtained from freshly isolated MM patients' BM using 
CD138
+ 
microbeads selection, as reported.
30
  
 
Statistical analyses. Statistical analyses were performed using Prism 6 (GraphPad Software). 
Student’s t test for unpaired data (2-tailed) was used to test the probability of significant differences 
between two groups of samples. For more than two groups of samples, data were analyzed with a 1-
way analysis of variance and corrected by the Bonferroni multiple comparison test. Tumor volume 
data were analyzed with a 2-way analysis of variance and corrected by the Bonferroni test. 
Differences were considered significant when p< 0.05 unless otherwise specified.  
 
Data sharing statement. For original data, please contact arianna.giacomini@unibs.it. Microarray 
data are available at GEO under accession number GSE129279.  
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RESULTS  
 
Inhibition of FGF/FGFR signaling triggers apoptosis of MM cells.  
The human MM cell lines harbouring (KMS-11 and OPM-2 cells) or not (RPMI8226 and U-266 
cells) the t(4;14) translocation express different FGFs and FGFRs (Figure S1A). Autocrine 
activation of the FGF/FGFR system in these cells was confirmed by FGFR/FRS2 phosphorylation 
that occurs in the absence of exogenous stimuli (Figure S1A). When treated with the pan-FGF trap 
NSC12,
25,26
 t(4;14)-positive and t(4;14)-negative MM cells showed impaired cell proliferation and 
survival, with alterations of cell cycle (Figure 1A-C). Both KMS-11 and RPMI8226 cells showed a 
significant increase of apoptotic cells 6 hours after NSC12 treatment with 100% cell death at 24 
hours (Figures 1C and S1B). Accordingly, NSC12 inhibited FGFR3 phosphorylation, activation of 
MAPK, Akt and JAK/STAT3 pathways and reduced the levels of the anti-apoptotic protein mcl-1, 
leading to the activation of caspase 3 in both cell lines (Figure 1D). Similar results were obtained 
after treatment with the TK FGFR inhibitor BGJ398 (Figure S1C-E). A significant reduction of 
MM cell survival was observed also when KMS-11 cells were co-cultured with patient-derived 
BMSCs and treated with NSC12, suggesting that FGF trapping might disrupt FGF-mediated 
BMSC/MM cell cross/talk (Figure S1F-G).    
In keeping with the in vitro observations, oral treatment with NSC12 caused a significant inhibition 
of FGFR3 phosphorylation (Figure 2A) and tumor growth when KMS-11 and RPMI8226 cells 
were grafted s.c. in immunodeficient mice (Figure 2B). This was accompanied by inhibition of 
tumor cell proliferation and increased apoptosis, as revealed by phospho-Histone H3 and TUNEL 
immunostaining, respectively (Figure 2C). In keeping with the role of the FGF/FGFR system in 
tumor angiogenesis, NSC12-treated tumors showed also a decrease in CD31
+
 vascularization 
(Figure S1H). 
 
FGF trapping inhibits MM dissemination.  
The MM.1S cell line represents an experimental platform suitable for the study of MM 
dissemination in vivo.
31,32
 MM.1S cells express all four FGFRs and FGF2/3/9 (Figure S1A). 
NSC12 administration hampered FGFR1 and FGFR3 phosphorylation also in these cells (Figure 
3A), thus inhibiting their proliferation and increasing the number of apoptotic cells at 6 hours after 
treatment onward (Figure 3B). Notably, NSC12-treated cells were characterized by a decreased 
capacity to migrate towards chemotactic stimuli represented by FBS or the SDF1 chemokine 
(Figure 3C). FAK kinase and -catenin are regulated by FGF/FGFR signaling33-36 and support the 
migration and adhesion of MM cells in the BM niche.
37,38
 Accordingly, NSC12 strongly reduced 
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FAK phosphorylation and the levels of FAK and -catenin in MM.1S cells (Figure 3D), indicating 
a link between the FGF/FGFR axis and MM cell migration. 
To investigate whether NSC12 might affect the homing of MM cells to the BM, we took advantage 
of a zebrafish embryo model in which the caudal hematopoietic tissue (CHT) recapitulates a BM-
like niche.
29
 MM.1S cells were stained with a red or blue fluorescent dye and treated with vehicle 
(DMSO) or NSC12, respectively. After 3 hours, an incubation time that does not cause MM.1S cell 
death, the two cell preparations were mixed together (1:1 ratio) and co-injected in the bloodstream 
of zebrafish embryos (Figure 3E). As shown in Figure 3F, NSC12 pre-treatment significantly 
prevented MM cell homing to the CHT when compared to DMSO-treated cells.  
Next, GFP/luciferase-expressing MM.1S cells were systemically injected in SCID beige mice. BM 
infiltration was detectable 2 weeks after injection and reached a peak after 6-8 weeks, when 
approximately 40% of the BM cell population was represented by tumor cells (Figure 3G). On this 
basis, mice bearing 10-20% of MM.1S cell BM colonization/infiltration were treated for three days 
with NSC12. BM analysis showed that NSC12 reduced the levels of phosphorylated FGFR3 in 
NSC12-treated mice to those detected in disease-free animals (Figure 3H). Accordingly, chronic 
NSC12 treatment significantly reduced BM tumor burden in MM.1S cell-grafted animals (Figure 
3I). Together, these data indicate that NSC12 inhibits FGF/FGFR signaling and proliferation of 
MM cells growing within their own microenvironment. 
 
Inhibition of FGF signaling induces oxidative stress-mediated DNA damage and apoptosis in 
MM cells.  
To get further insights into the impact of FGF inhibition in MM, gene expression profiling (GEP) 
analysis was performed on NSC12-treated KMS-11 cells. The analysis revealed a significant Log2 
2-fold upregulation of 33 and 44 genes after 6 and 12 hours of treatment, respectively (Figure 4A, 
Figure S2A), the majority of them being related to oxidative stress and DNA damage (Table S1, 
Figure S2B). Accordingly, phospho-kinase array analysis showed the activation of oxidative stress 
and DNA damage-induced protein kinases and confirmed the inactivation of Akt, Erk and STAT 
kinases as well as reduced levels of FAK and -catenin phosphorylation (Figure S2C). Together, 
these data suggest that the autocrine FGF/FGFR axis may play a role in preventing oxidative stress 
and consequent DNA damage in MM cells.   
In keeping with this hypothesis, NSC12 rapidly increased mtROS production and mitochondrial 
membrane depolarization in KMS-11 (Figure 4B) and RPMI8226 (Figure S2D) cells. mtROS 
production was paralleled by PARP inactivation and extensive DNA damage, as assessed by 
increased levels of phospho-H2AX (H2AX) (Figure 4C). Accordingly, NSC12 caused a strong 
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reduction of mitochondrial respiration 1 hour after treatment and a complete dysfunction of 
mitochondrial activity 3 hours thereafter, leading to mitochondrial proton leak and medium 
acidification (Figures 4D and S2E). Oxidative stress and DNA damage were observed also in 
tumor xenografts treated with NSC12, as assessed by anti-nitro tyrosine and anti-pH2AX staining, 
respectively (Figure 4E). Notably, administration of the antioxidant vitamin E
39
 prevented NSC12-
induced mtROS production, mitochondrial depolarization, DNA damage and apoptosis in MM cells 
(Figures 4F-G and S2F) without affecting the capacity of the compound to inhibit FGFR 
phosphorylation (Figure 4G). Accordingly, overexpression of mitochondrial catalase
28
, but not 
cytoplasmic catalase, significantly reduced mtROS production and cell death in NSC12-treated 
KMS-11 cells (Figure S2G). Finally, vitamin E exerted a rescue effect also when FGFR signaling 
was inhibited by the TK FGFR inhibitor BGJ398 (Figure S2F). Together, these data highlight the 
capacity of the autocrine FGF/FGFR axis to prevent mitochondrial oxidative stress, thus allowing 
cell survival in MM.  
 
c-Myc degradation mediates oxidative stress and apoptosis induced by FGF inhibition in MM 
cells.  
In order to understand the mechanism by which the inhibition of FGF signaling triggers oxidative 
stress-induced cell death in MM, GSEA of GEP data was performed on NSC12-treated KMS-11 
cells. In agreement with the impact of NSC12 on MM cell proliferation/survival and migration, 
GSEA showed the enrichment of mitotic spindle, G2/M checkpoint and wnt/-catenin signaling 
hallmarks that were significantly down-modulated after NSC12 treatment (Figure S3A). GSEA 
revealed also the down-modulation of c-Myc targets (Figure 5A), confirmed by RT-qPCR (Figure 
S3B). Accordingly, a rapid disappearance of c-Myc protein occurred in MM cells after NSC12 
treatment (Figures 5B and S3C) in the absence of significant changes of c-MYC mRNA levels at 3 
and 6 hours of NSC12 treatment (Figure S3D), suggesting that FGF inhibition may induce 
proteasomal degradation of c-Myc protein. Indeed, the proteasome inhibitor MG132 prevented c-
Myc protein degradation triggered by NSC12 in KMS-11 cells (Figure 5C).  
GSK3 kinase is a FGFR-mediated modulator of proteasomal c-Myc degradation.33,40-43 NSC12 
inhibited GSK3kinase phosphorylation, leading to the activation of this kinase (Figure 5B).44 A 
significant reduction of c-Myc and phospho-GSK3 kinase levels was observed also in NSC12-
treated KMS-11 tumor xenografts (Figure 5B), suggesting that GSK3 kinase activation 
following FGF trapping may induce c-Myc proteasomal degradation, leading to down-regulation of 
c-Myc target genes.  
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To assess the role of c-Myc degradation in oxidative stress and apoptosis induced by FGF inhibition 
in MM cells, we generated KMS-11 cells overexpressing the undegradable T58A mutant form of c-
Myc.
45,46
 Ectopic expression of the c-Myc
(T58A)
 mutant prevented NSC12-induced c-Myc 
degradation (Figure 5D) and blocked NSC12-induced production of mtROS, thus preserving MM 
cells from apoptosis (Figure 5E).  
The intracellular content of the anti-oxidant glutathione (GSH) is depleted upon c-Myc down-
regulation, thus mediating c-Myc-dependent drug-induced apoptosis.
47
 Accordingly, GSH levels 
were strongly reduced in NSC12-treated KMS-11 (Figure 5F) and RPMI8226 (Figure S3E) cells, 
but not in Myc
(T58A)
 KMS-11 cells (Figure 5G). Notably, vitamin E did not significantly prevent 
GSH depletion upon treatment with NSC12 (Figure 5H), suggesting that GSH depletion might 
represent an upstream event in the oxidative stress cascade triggered by c-Myc degradation 
following inhibition of the autocrine FGF/FGFR system in MM cells.  
  
NSC12 induces oxidative stress and cell death in newly diagnosed and refractory/relapsed 
patient-derived MM cells.  
To assess the therapeutic implications consequent to FGF inhibition in MM, tumor cells freshly 
isolated from 26 MM patients (Table 1) were treated with NSC12 and assessed for cell death. 
Twenty-two cases responded to NSC12 regardless of t(4;14) translocation (Figure 6A, Tables 1). 
Interestingly, NSC12 was efficacious in both newly diagnosed (10/10) and refractory/relapsed 
(12/16) patients (Table 1). In both cases, western blot analysis showed a strong inhibition of 
FGFR3, ERK1/2, JAK2 and STAT3 phosphorylation, reduction of mcl-1 levels, and caspase 3 
activation (Figure 6B). Only a limited effect, in the absence of caspase 3 activation (Figure S4), 
was exerted by the highest dose of NSC12 on PBMCs isolated from eight healthy donors, being 
totally ineffective at lower doses (Figure 6A).  
As observed for MM cell lines, NSC12 caused a drastic reduction of c-Myc protein from both 
newly diagnosed and relapsed/refractory patients (Figure 6C), paralleled by increased oxidative 
stress and DNA damage, as assessed by RT-qPCR analysis (Figure 6D) and anti-nitro tyrosine and 
phospho-H2AX staining (Figure 6E). Again, vitamin E rescued patient-derived MM cells from 
NSC12-induced cell death (Figure 6F).  
Notably, no significant differences in NSC12 sensitivity were observed between MM cells from 
refractory/relapsed or newly diagnosed patients (Figure 7A). Accordingly, Bortezomib-resistant 
KMS-11/BTZ cells
48
 responded in vitro and in vivo to NSC12 treatment in a manner similar to 
parental KMS-11 cells (Figures 7B-E), suggesting that FGF trapping may represent a therapeutic 
approach for MM cases relapsed from or not responding to proteasome inhibitor-based treatments. 
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In this frame, GEP (Table S1) and RT-qPCR (Figure 7F) analyses revealed a significant down-
regulation of TXNDC5 and of the c-Myc target PRDX3 genes in NSC12-treated KMS-11 and KMS-
11/BTZ cells (Figure 7F). The two genes are involved in the protection from oxidative stress and 
Bortezomib resistance in refractory/relapsed MM.
49
 Altogether, these findings indicate that 
inhibition of the FGF/FGFR system may represent a promising approach to eradicate Bortezomib-
refractory MM cells.  
 
DISCUSSION  
Here we show for the first time that autocrine FGF/FGFR signaling protects MM cells from 
oxidative stress-induced apoptosis, thus playing a non-redundant role in MM cell survival. Based on 
a FGF trapping approach, we demonstrate that FGF blockade induces the degradation of the 
oncoprotein c-Myc; this causes GSH depletion and triggers mitochondrial oxidative stress, DNA 
damage and apoptosis in MM cells. 
NSC12 acts as an extracellular pan FGF trap, exerting an oncosuppressive activity on FGF-
dependent solid tumors.
25,26
 Here, we demonstrate that NSC12 blocks MM cell proliferation and 
induces oxidative stress-dependent MM apoptotic cell death in both t(4;14)-positive and t(4;14)-
negative MM cells. Notably, NSC12 causes a significant inhibition of MM cell survival also when 
MM cells are co-cultured with patient-derived BMSCs, suggesting that FGF trapping may disrupt 
FGF-mediated MM/BMS cells cross-talk. Accordingly, NSC12 inhibited the activation of 
FGF/FGFR signaling in MM cells growing in their own microenvironment after BM colonization 
and reduced BM tumor burden, pointing to a non-redundant role of the FGF/FGFR system in MM 
dissemination. In keeping with this hypothesis, NSC12 affected MM cell migration by reducing 
FAK activation and -catenin protein levels and hampered MM cell homing to the zebrafish 
embryo BM-like niche.   
GEP and phospho-protein array analyses demonstrated a significant increase of gene expression and 
protein phosphorylation events associated to oxidative stress and DNA damage in NSC12-treated 
KMS-11 cells. Accordingly, NSC12 rapidly increased mtROS production, membrane 
depolarization and mitochondrial dysfunction, paralleled by PARP inactivation and extensive DNA 
damage. This was prevented by the antioxidant vitamin E or mitochondrial catalase overexpression, 
indicating that mitochondrial oxidative stress is directly responsible for MM cell apoptosis upon 
FGF inhibition.  
Oxidative stress-inducing agents have been approved for the treatment of solid malignancies and 
various types of leukemias and lymphomas.
50
 Several evidences suggest that affecting the 
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intracellular redox status may represent a promising strategy also in MM. Indeed, elevated serum 
levels of oxidative stress markers are found in MM patients.
51-53
 In addition, upregulation of the 
antioxidant superoxide dismutase-1 and epigenetic silencing of the oxidative stress sensitizer 
glutathione peroxidase 3 gene are associated to MM progression and poor prognosis.
54,55
 Also, the 
small nucleolar RNA ACA11 inhibits oxidative stress and is overexpressed in patient-derived 
t(4;14)-positive MM cells.
56
 Altogether, these findings indicate that the induction of ROS 
production by FGF/FGFR inhibitors may represent a novel anti-MM approach and suggest that the 
use of antioxidant supplements
57
 in the context of FGF/FGFR inhibitory therapies should be 
carefully evaluated. 
In keeping with data obtained from FGFR1 fusion-driven hematological malignancies
58
, we 
observed a significant down-modulation of c-Myc targets after FGF inhibition in MM cells. 
Accordingly, NSC12 induced the degradation of c-Myc protein that was inhibited by the 
proteasome inhibitor MG132. This was paralleled by activation of GSK3 kinase, a direct 
regulator of c-Myc degradation.
40-42
 In addition, ectopic expression of the undegradable c-Myc
(T58A)
 
mutant
45
 prevented NSC12-induced mtROS production and apoptosis in KMS-11 cells. Together, 
these findings point to a direct link between FGF signaling, c-Myc activity and cell survival in MM.  
c-Myc controls mitochondrial metabolism and homeostasis
59
 and upregulates the levels of 
mitochondrial glutaminase, leading to GSH synthesis.
60
 GSH prevents apoptosis due to ROS 
production consequent to redox imbalance or enhanced mitochondrial function in response to 
increased c-Myc activity.
61,62
 In keeping with these findings, recent evidences suggest that a large 
fraction of primary MM cells depends on c-Myc activity for survival.
63-65
 Our data show that FGF 
trapping causes a significant depletion of GSH levels in wild type KMS-11 cells but not in 
Myc
(T58A)
 mutants. This indicates that FGF/FGFR signaling protects MM cells from oxidative 
stress-mediated apoptosis through c-Myc-dependent regulation of GSH levels.  
Our findings were confirmed within the clinical setting using primary BM-derived plasma cells 
from MM patients. Twenty-two out of the 26 cases examined responded significantly to NSC12 
treatment regardless of t(4;14) chromosomal translocation. In agreement with the data obtained with 
MM cell lines, NSC12 treatment induced c-Myc degradation, ROS production and cell death that 
was prevented by the antioxidant vitamin E. These data confirm the pivotal role played by FGF 
autocrine/paracrine stimulation in MM and suggest FGF traps might represent a promising 
therapeutic approach in MM, including high-risk MM patients with the t(4;14) translocation.  
Notably, NSC12 reduced c-Myc protein levels and increased oxidative stress also in MM primary 
cells obtained from patients with relapsed/refractory disease. Accordingly, NSC12 treatment exerts 
a similar oncosuppressive effect on both Bortezomib-resistant KMS-11/BTZ
48
 and parental KMS-
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11 cells in vitro and in vivo, with inhibition of the expression of TXNDC5 and the c-Myc target 
PRDX3, both involved in the protection from oxidative stress and Bortezomib resistance in 
refractory/relapsed MM.
49
 Together with previous observations showing that perturbation of 
mitochondrial function may decrease the resistance of MM cells to Bortezomib,
66
 these findings 
suggest that molecules able to induce mitochondrial oxidative stress, including FGF/FGFR 
inhibitors, may represent a promising approach to eradicate proteasome inhibitor-
relapsed/refractory cancer cells.  
Four out of the 26 patient-derived MM cell cases tested showed a limited or no response to NSC12 
treatment. Our data point to c-Myc as a key downstream effector able to determine the therapeutic 
response to FGF/FGFR inhibitors in MM. Upregulation of c-Myc protein is related to MM disease 
initiation and progression, being activated in a large fraction of MM patients.
67-70
 Even though the 
presence of point mutations encoding for undegradable forms of c-Myc has not been reported for 
MM,
69
 recent observations have shown that PKC-dependent phosphorylation of GSK3 kinase 
causes its inactivation in gastric cancer,
43
 thus representing a possible mechanism of 
resistance/escape to anti-FGF therapies. Further studies will be required to get a deeper insight into 
the molecular mechanisms that allow or hamper the response to therapeutic approaches targeting 
the FGF/FGFR system in MM.      
  
FGF blockade triggers MM oxidative stress 
14 
 
ACKNOWLEDGMENTS 
This work was supported by grants from Fondazione Cariplo (grant n° 2016-0570) to A.G, 
Fondazione Regionale per la Ricerca Biomedica (FRRB, grant n° 2016-065 ERA-NET 
TRANSCAN-2) to A.M.R. and to C.C.-S. (FRRB, grant n° 2015-0042) and Associazione Italiana 
Ricerca sul Cancro to M.P. (AIRC grant n° 18943), R.R. (AIRC grant n° MFAG 18459) and C.C.-
S. (AIRC grant n° 20575). E.G. and S.M. were supported by Fondazione Italiana per la Ricerca sul 
Cancro Fellowships and F.M. by a Fondazione Veronesi Fellowship.  
The authors are grateful to Daniela Uberti and Mattia Bugatti for technical support.  
 
AUTHOR CONTRIBUTIONS 
R.R. conceived in vitro and in vivo experiments, analysed the data and revised the manuscript; 
G.C.G. performed in vitro experiments; F.M. performed in vivo experiments; A.S. and S.L.L. 
isolated patient-derived MM cells and performed in vitro experiments; E.F. and S.T. performed in 
vitro experiments; E.G. performed seahorse experiments; S.M. performed in vitro experiments; 
R.C. synthetized NSC12; G.P. performed experiments with zebrafish; V.D. isolated patient-derived 
MM cells and performed in vitro experiments; N.C. and A.C. analysed GEP data; M.M. conceived 
NSC12 synthesis; C.C-S., A.B. and A.R. collected BM samples; M.P. conceived experiments and 
revised the manuscript; A.G. conceived and performed in vitro experiments, performed histological 
analyses, analysed the data and wrote the manuscript.  
 
DECLARATION OF INTERESTS 
The authors declare no competing interests 
 
REFERENCES 
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-
30. 
2. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 
2009;374(9686):324-339. 
3. Bommert K, Bargou RC, Stuhmer T. Signalling and survival pathways in multiple myeloma. 
Eur J Cancer. 2006;42(11):1574-1580. 
4. van de Donk NW, Lokhorst HM, Bloem AC. Growth factors and antiapoptotic signaling 
pathways in multiple myeloma. Leukemia. 2005;19(12):2177-2185. 
5. Ria R, Reale A, De Luisi A, Ferrucci A, Moschetta M, Vacca A. Bone marrow angiogenesis 
and progression in multiple myeloma. Am J Blood Res. 2011;1(1):76-89. 
6. Ribatti D, Vacca A. New Insights in Anti-Angiogenesis in Multiple Myeloma. Int J Mol Sci. 
2018;19(7). 
7. Vacca A, Ribatti D, Roccaro AM, Frigeri A, Dammacco F. Bone marrow angiogenesis in 
patients with active multiple myeloma. Semin Oncol. 2001;28(6):543-550. 
FGF blockade triggers MM oxidative stress 
15 
 
8. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic 
potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple 
myeloma. Blood. 1999;93(9):3064-3073. 
9. Bisping G, Leo R, Wenning D, et al. Paracrine interactions of basic fibroblast growth factor 
and interleukin-6 in multiple myeloma. Blood. 2003;101(7):2775-2783. 
10. Lentzsch S, Chatterjee M, Gries M, et al. PI3-K/AKT/FKHR and MAPK signaling cascades are 
redundantly stimulated by a variety of cytokines and contribute independently to proliferation 
and survival of multiple myeloma cells. Leukemia. 2004;18(11):1883-1890. 
11. Otsuki T, Yamada O, Yata K, et al. Expression of fibroblast growth factor and FGF-receptor 
family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and 
FGFR3 translocation. Int J Oncol. 1999;15(6):1205-1212. 
12. Di Raimondo F, Azzaro MP, Palumbo G, et al. Angiogenic factors in multiple myeloma: higher 
levels in bone marrow than in peripheral blood. Haematologica. 2000;85(8):800-805. 
13. Sato N, Hattori Y, Wenlin D, et al. Elevated level of plasma basic fibroblast growth factor in 
multiple myeloma correlates with increased disease activity. Jpn J Cancer Res. 
2002;93(4):459-466. 
14. Sezer O, Jakob C, Eucker J, et al. Serum levels of the angiogenic cytokines basic fibroblast 
growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor 
(HGF) in multiple myeloma. Eur J Haematol. 2001;66(2):83-88. 
15. Walsh S, Jefferiss C, Stewart K, Jordan GR, Screen J, Beresford JN. Expression of the 
developmental markers STRO-1 and alkaline phosphatase in cultures of human marrow stromal 
cells: regulation by fibroblast growth factor (FGF)-2 and relationship to the expression of FGF 
receptors 1-4. Bone. 2000;27(2):185-195. 
16. Plowright EE, Li Z, Bergsagel PL, et al. Ectopic expression of fibroblast growth factor receptor 
3 promotes myeloma cell proliferation and prevents apoptosis. Blood. 2000;95(3):992-998. 
17. Grand EK, Chase AJ, Heath C, Rahemtulla A, Cross NC. Targeting FGFR3 in multiple 
myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia. 
2004;18(5):962-966. 
18. Trudel S, Ely S, Farooqi Y, et al. Inhibition of fibroblast growth factor receptor 3 induces 
differentiation and apoptosis in t(4;14) myeloma. Blood. 2004;103(9):3521-3528. 
19. Trudel S, Li ZH, Wei E, et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for 
the potential treatment of t(4;14) multiple myeloma. Blood. 2005;105(7):2941-2948. 
20. Trudel S, Stewart AK, Rom E, et al. The inhibitory anti-FGFR3 antibody, PRO-001, is 
cytotoxic to t(4;14) multiple myeloma cells. Blood. 2006;107(10):4039-4046. 
21. Kalff A, Spencer A. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: 
prognostic implications and current clinical strategies. Blood Cancer J. 2012;2:e89. 
22. Intini D, Baldini L, Fabris S, et al. Analysis of FGFR3 gene mutations in multiple myeloma 
patients with t(4;14). Br J Haematol. 2001;114(2):362-364. 
23. Krejci P, Mekikian PB, Wilcox WR. The fibroblast growth factors in multiple myeloma. 
Leukemia. 2006;20(6):1165-1168. 
24. Giacomini A, Chiodelli P, Matarazzo S, Rusnati M, Presta M, Ronca R. Blocking the 
FGF/FGFR system as a "two-compartment" antiangiogenic/antitumor approach in cancer 
therapy. Pharmacol Res. 2016;107:172-185. 
25. Castelli R, Giacomini A, Anselmi M, et al. Synthesis, Structural Elucidation, and Biological 
Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the 
Treatment of FGF-Dependent Lung Tumors. J Med Chem. 2016;59(10):4651-4663. 
26. Ronca R, Giacomini A, Di Salle E, et al. Long-Pentraxin 3 Derivative as a Small-Molecule 
FGF Trap for Cancer Therapy. Cancer Cell. 2015;28(2):225-239. 
27. Bono F, De Smet F, Herbert C, et al. Inhibition of tumor angiogenesis and growth by a small-
molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell. 2013;23(4):477-
488. 
FGF blockade triggers MM oxidative stress 
16 
 
28. Gurgul E, Lortz S, Tiedge M, Jorns A, Lenzen S. Mitochondrial catalase overexpression 
protects insulin-producing cells against toxicity of reactive oxygen species and 
proinflammatory cytokines. Diabetes. 2004;53(9):2271-2280. 
29. Sacco A, Roccaro AM, Ma D, et al. Cancer Cell Dissemination and Homing to the Bone 
Marrow in a Zebrafish Model. Cancer Res. 2016;76(2):463-471. 
30. Roccaro AM, Mishima Y, Sacco A, et al. CXCR4 Regulates Extra-Medullary Myeloma 
through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Rep. 
2015;12(4):622-635. 
31. Greenstein S, Krett NL, Kurosawa Y, et al. Characterization of the MM.1 human multiple 
myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and 
signaling of steroid-sensitive and -resistant MM cells. Exp Hematol. 2003;31(4):271-282. 
32. Lwin ST, Edwards CM, Silbermann R. Preclinical animal models of multiple myeloma. 
Bonekey Rep. 2016;5:772. 
33. Hashimoto M, Sagara Y, Langford D, et al. Fibroblast growth factor 1 regulates signaling via 
the glycogen synthase kinase-3beta pathway. Implications for neuroprotection. J Biol Chem. 
2002;277(36):32985-32991. 
34. Hunger-Glaser I, Fan RS, Perez-Salazar E, Rozengurt E. PDGF and FGF induce focal adhesion 
kinase (FAK) phosphorylation at Ser-910: dissociation from Tyr-397 phosphorylation and 
requirement for ERK activation. J Cell Physiol. 2004;200(2):213-222. 
35. Katoh M, Katoh M. Cross-talk of WNT and FGF signaling pathways at GSK3beta to regulate 
beta-catenin and SNAIL signaling cascades. Cancer Biol Ther. 2006;5(9):1059-1064. 
36. Mavila N, James D, Utley S, et al. Fibroblast growth factor receptor-mediated activation of 
AKT-beta-catenin-CBP pathway regulates survival and proliferation of murine hepatoblasts 
and hepatic tumor initiating stem cells. PLoS One. 2012;7(11):e50401. 
37. Qiang YW, Walsh K, Yao L, et al. Wnts induce migration and invasion of myeloma plasma 
cells. Blood. 2005;106(5):1786-1793. 
38. Park SY, Wolfram P, Canty K, et al. Focal adhesion kinase regulates the localization and 
retention of pro-B cells in bone marrow microenvironments. J Immunol. 2013;190(3):1094-
1102. 
39. Traber MG, Atkinson J. Vitamin E, antioxidant and nothing more. Free Radic Biol Med. 
2007;43(1):4-15. 
40. Henriksson M, Bakardjiev A, Klein G, Luscher B. Phosphorylation sites mapping in the N-
terminal domain of c-myc modulate its transforming potential. Oncogene. 1993;8(12):3199-
3209. 
41. Robertson H, Hayes JD, Sutherland C. A partnership with the proteasome; the destructive 
nature of GSK3. Biochem Pharmacol. 2018;147:77-92. 
42. Welcker M, Orian A, Jin J, et al. The Fbw7 tumor suppressor regulates glycogen synthase 
kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A. 
2004;101(24):9085-9090. 
43. Lau WM, Teng E, Huang KK, et al. Acquired Resistance to FGFR Inhibitor in Diffuse-Type 
Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3beta. 
Mol Cancer Ther. 2018;17(1):232-242. 
44. Fang X, Yu SX, Lu Y, Bast RC, Jr., Woodgett JR, Mills GB. Phosphorylation and inactivation 
of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A. 
2000;97(22):11960-11965. 
45. Liu H, Ai J, Shen A, et al. c-Myc Alteration Determines the Therapeutic Response to FGFR 
Inhibitors. Clin Cancer Res. 2017;23(4):974-984. 
46. Sears RC. The life cycle of C-myc: from synthesis to degradation. Cell Cycle. 2004;3(9):1133-
1137. 
FGF blockade triggers MM oxidative stress 
17 
 
47. Biroccio A, Benassi B, Fiorentino F, Zupi G. Glutathione depletion induced by c-Myc 
downregulation triggers apoptosis on treatment with alkylating agents. Neoplasia. 
2004;6(3):195-206. 
48. Ri M, Iida S, Nakashima T, et al. Bortezomib-resistant myeloma cell lines: a role for mutated 
PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia. 
2010;24(8):1506-1512. 
49. Dytfeld D, Luczak M, Wrobel T, et al. Comparative proteomic profiling of refractory/relapsed 
multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy. 
Oncotarget. 2016;7(35):56726-56736. 
50. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat 
Rev Drug Discov. 2013;12(12):931-947. 
51. Gangemi S, Allegra A, Alonci A, et al. Increase of novel biomarkers for oxidative stress in 
patients with plasma cell disorders and in multiple myeloma patients with bone lesions. 
Inflamm Res. 2012;61(10):1063-1067. 
52. Mehdi WA, Zainulabdeen JA, Mehde AA. Investigation of the antioxidant status in multiple 
myeloma patients: effects of therapy. Asian Pac J Cancer Prev. 2013;14(6):3663-3667. 
53. Sharma A, Tripathi M, Satyam A, Kumar L. Study of antioxidant levels in patients with 
multiple myeloma. Leuk Lymphoma. 2009;50(5):809-815. 
54. Kaiser MF, Johnson DC, Wu P, et al. Global methylation analysis identifies prognostically 
important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood. 
2013;122(2):219-226. 
55. Salem K, McCormick ML, Wendlandt E, Zhan F, Goel A. Copper-zinc superoxide dismutase-
mediated redox regulation of bortezomib resistance in multiple myeloma. Redox Biol. 
2015;4:23-33. 
56. Chu L, Su MY, Maggi LB, Jr., et al. Multiple myeloma-associated chromosomal translocation 
activates orphan snoRNA ACA11 to suppress oxidative stress. J Clin Invest. 
2012;122(8):2793-2806. 
57. Moss RW. Should patients undergoing chemotherapy and radiotherapy be prescribed 
antioxidants? Integr Cancer Ther. 2006;5(1):63-82. 
58. Hu T, Wu Q, Chong Y, et al. FGFR1 fusion kinase regulation of MYC expression drives 
development of stem cell leukemia/lymphoma syndrome. Leukemia. 2018;32(11):2363-2373. 
59. Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal 
Transduct Target Ther. 2018;3:5. 
60. Gao P, Tchernyshyov I, Chang TC, et al. c-Myc suppression of miR-23a/b enhances 
mitochondrial glutaminase expression and glutamine metabolism. Nature. 
2009;458(7239):762-765. 
61. Bansal A, Simon MC. Glutathione metabolism in cancer progression and treatment resistance. 
J Cell Biol. 2018;217(7):2291-2298. 
62. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency in glutamine but 
not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol. 2007;178(1):93-
105. 
63. Holien T, Vatsveen TK, Hella H, Waage A, Sundan A. Addiction to c-MYC in multiple 
myeloma. Blood. 2012;120(12):2450-2453. 
64. Kuehl WM, Bergsagel PL. MYC addiction: a potential therapeutic target in MM. Blood. 
2012;120(12):2351-2352. 
65. Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature. 
2008;454(7201):226-231. 
66. Song IS, Kim HK, Lee SR, et al. Mitochondrial modulation decreases the bortezomib-
resistance in multiple myeloma cells. Int J Cancer. 2013;133(6):1357-1367. 
FGF blockade triggers MM oxidative stress 
18 
 
67. Chng WJ, Huang GF, Chung TH, et al. Clinical and biological implications of MYC activation: 
a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia. 
2011;25(6):1026-1035. 
68. Cobbold LC, Wilson LA, Sawicka K, et al. Upregulated c-myc expression in multiple myeloma 
by internal ribosome entry results from increased interactions with and expression of PTB-1 
and YB-1. Oncogene. 2010;29(19):2884-2891. 
69. Dib A, Gabrea A, Glebov OK, Bergsagel PL, Kuehl WM. Characterization of MYC 
translocations in multiple myeloma cell lines. J Natl Cancer Inst Monogr. 2008(39):25-31. 
70. Holien T, Misund K, Olsen OE, et al. MYC amplifications in myeloma cell lines: correlation 
with MYC-inhibitor efficacy. Oncotarget. 2015;6(26):22698-22705. 
 
  
FGF blockade triggers MM oxidative stress 
19 
 
Pt. DIAGNOSIS SEX AGE t(4;14) 
RESPONSE 
TO NSC12 
CELL DEATH (%) 
DMSO 
NSC12 
3 M 6 M 10 M 
1 ND M 68 n.d. yes 27.2 - 91.7 94.5 
2 ND M 67 negative yes 15.9 21.6 23.8 73.3 
3 ND M 88 negative yes 14.3 16.4 37.2 85.3 
4 R/R F 67 negative yes 11.5 12.4 21.1 61.7 
5 ND F 64 positive yes 16.0 20.4 35.5 79.9 
6 R/R M 66 negative no 36.0 39.9 43.5 53.5 
7 R/R F 51 positive yes 39.5 50.7 53.8 76.9 
8 R/R F 79 negative yes 44.0 49.7 54.7 68.3 
9 ND F 72 negative yes 30.5 36.9 83.3 - 
10 R/R F 55 negative no 7.3 11.0 13.3 15.7 
11 R/R F 66 negative yes 21.2 37.7 46.4 46.6 
12 R/R M 51 negative yes 5.3 27.5 56.4 55.0 
13 ND M 45 negative yes 4.3 23.5 40.6 66.1 
14 R/R F 66 n.d. no 31.5 24.4 27.5 23.1 
15 R/R F 64 negative yes 11.0 69.3 87.8 89.3 
16 ND M 64 negative yes 20.7 25.8 34.8 52.4 
17 ND M 53 n.d. yes 3.7 7.4 25.1 91.2 
18 R/R M 57 n.d. yes 5.1 21.7 22.7 63.5 
19 R/R F 73 n.d. yes 26.6 35.7 46.0 64.2 
20 ND F 68 n.d. yes 5.0 12.0 32.6 83.8 
21 R/R M 73 n.d. yes 2.9 5.9 25.1 76.3 
22 R/R M 75 n.d. yes 7.7 12.2 31.4 87.4 
23 R/R M 65 negative yes 31.9 - - 68.6 
24 R/R M 69 negative yes 25.6 - - 57.3 
25 R/R F 65 positive no 10.8 - - 21.9 
26 ND M 61 n.d. yes 31.3 - - 71.6 
 
Table 1.  Patient-derived MM cells treated with NSC12. Individual response of patient-derived 
MM cells to NSC12 treatment. Data are the mean of three replicates.  
ND: Newly Diagnosed; R/R: Relapsed/Refractory; n.d.: not determined.  
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FIGURE LEGENDS 
 
Figure 1. In vitro effects of FGF blockade in MM cells. 
(A) Viable cell counts by cytofluorimetric analysis of MM cell lines harbouring or not the t(4;14) 
and treated with NSC12 for 72 hours. Data are mean ± SEM. 
(B) Cell cycle analysis of MM cell lines harbouring or not the t(4;14) and treated with NSC12 for 
72 hours. Data are mean ± SEM. **p < 0.01, #p < 0.001.   
(C) Cytofluorimetric analysis of apoptotic cell death of t(4;14)-positive KMS-11 and t(4;14)-
negative RPMI8226 cells after treatment with NSC12 6 M. 
(D) Western blot analysis of KMS-11 and RPMI8226 cells after treatment with NSC12 6 M.  
 
Figure 2. FGF trapping inhibits MM growth in vivo. 
(A) Analysis of phospho-FGFR3 levels by immunofluorescence (left panel) and western blot (right 
panels) in s.c. KMS-11 alginate plugs after 4-days oral treatment with NSC12 7.5 mg/Kg (n= 4 
mice/group). pFGFR3/FGFR3 densitometry was quantified with ImageJ software and normalized to 
-actin. Scale bar 100 m. 
(B) Tumor growth of KMS-11 and RPMI8226 cells injected s.c. and orally treated (arrows) with 
NSC12 or vehicle (n = 10 mice/group). 
(C) Immunohistochemical analysis of KMS-11 and RPMI8226 tumors harvested at the end of the 
experiment described in (B). Quantification of pHH3- and TUNEL-positive cells was carried out by 
ImageJ software. Scale bar 50 m. 
Data are mean ± SEM. In box and whiskers graphs, boxes extend from the 25th to the 75th 
percentiles, lines indicate the median values, and whiskers indicate the range of values.  
*p < 0.05, #p < 0.001.  
 
Figure 3. FGF inhibition hampers MM dissemination.   
(A) Western blot analysis of phospho-FGFR1 and phospho-FGFR3 levels in MM.1S cells treated 
with NSC12 6 M. 
(B) Viable cell counts and apoptotic cell death by cytofluorimetric analysis of NSC12-treated 
MM.1S cells.  
(C) Quantification of MM.1S cells migrated towards chemotactic stimuli in a chemiotaxis assay.  
(D) Western blot analysis of phospho and total FAK, and -catenin levels in MM.1S cells treated 
with NSC12 6 M. 
FGF blockade triggers MM oxidative stress 
21 
 
(E-F) DMSO- or NSC12-treated MM.1S cells (6 M for 3 hours) were stained with red or blue 
fluorescent dye, respectively, injected in the Zebrafish Cuvier Duct and assessed for their ability to 
migrate to the zebrafish caudal hematopoietic tissue (CHT) (E). Fluorescent area of MM.1S cells 
inside or outside the CHT were quantified by ImageJ software (F). (n = 33 zebrafish 
embryos/group).  
(G) Cytofluorimetric analysis of BM colonization by GFP/Luciferase-expressing MM.1S eight 
weeks after i.v. injection in SCID beige mice.    
(H) GFP/Luciferase-expressing MM.1S cells were injected i.v. in SCID beige mice; when 10-20% 
of BM disease infiltration was achieved, mice received a 3-days course of NSC12 treatment and 
western blot analysis of BM lysates after femur flushing was performed. (n = 3 mice/group). 
(I) SCID beige mice were injected i.v. with GFP/Luciferase-expressing MM.1S cells and treated 
every other day for 4 weeks with NSC12 7.5 mg/Kg or vehicle (n = 12 mice/group). 
Bioluminescence imaging (left panel) and quantification (right panel) of luciferase-expressing 
MM.1S cells are shown.   
Data are mean ± SEM. *p < 0.05, #p < 0.001.  
 
Figure 4. FGF inhibition induces oxidative stress-mediated apoptosis in MM cells. 
(A) Vulcano plot (left panel) and hierarchical clustering (right panel) of Log2 2-fold differentially 
expressed genes (p < 0.01) in KMS-11 cells treated with NSC12 6 M for 12 hours. 
(B) Cytofluorimetric analysis of mtROS production (Mitosox) and mitochondrial membrane 
depolarization (TMRE) in NSC12-treated KMS-11 cells. 
(C) Western blot analysis of PARP inactivation and phospho-H2AX (H2AX) expression in KMS-
11 cells treated with NSC12 6 M. 
(D) Analysis of mitochondrial activity by Seahorse assay for oxygen consumption rate (OCR) in 
KMS-11 cells treated with NSC12 6 M.  
(E) Anti-nitro tyrosine and anti-pH2AX staining of s.c. KMS-11 and RPMI8226 tumors grown in 
NSC12- or vehicle-treated mice (n = 5 mice/group). Scale bar 50 m. 
(F-G) Cytofluorimetric (F) and western blot analyses (G) of KMS-11 cells treated with NSC12 6 
M for 12 hours in the presence or absence of Vitamin E.   
Data are mean ± SEM. #p < 0.001.  
  
Figure 5. Oxidative stress-induced apoptosis following FGF inhibition is c-Myc-dependent.  
(A) Gene Set Enrichment Analysis (GSEA) for c-Myc targets in KMS-11 cells treated with NSC12 
6 M for 12 hours.  
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(B) Western blot analysis of KMS-11 cells treated with NSC12 6 M (upper panel) and KMS-11 
s.c. tumors (lower panel) grown in NSC12- or vehicle-treated mice.    
(C) Western blot analysis of c-Myc levels in KMS-11 cells treated with NSC12 6 M for 3 hours in 
the presence or absence of the proteasome inhibitor MG132. 
(D) Western blot analysis of c-Myc levels in WT and Myc
(T58A)
 mutant KMS-11 cells treated with 
NSC12 6 M for 3 hours.  
(E) Cytofluorimetric analysis of mtROS production and apoptotic cell death in WT and Myc
(T58A)
 
mutant KMS-11 cells after 12 hours of NSC12 treatment.    
(F) Cytofluorimetric analysis of intracellular GSH content in KMS-11 cells after treatment with 
NSC12 6 M. 
(G) Cytofluorimetric analysis of intracellular GSH content in WT and Myc
(T58A)
 mutant KMS-11 
cells treated with NSC12 6 M for 12 hours. Values of GSH median fluorescence intensity are 
reported in the histogram plot.   
(H) Cytofluorimetric analysis of intracellular GSH content in KMS-11 cells treated with NSC12 6 
M for 12 hours in the presence or absence of Vitamin E.  
Data are mean ± SEM. *p < 0.05, #p < 0.001.  
 
Figure 6. Effect of FGF trapping in patient-derived MM cells. 
(A) Analysis of patient-derived MM cell death after 12 hours of treatment with increasing doses of 
NSC12. Only NSC12 responsive MM cases are reported (22 cases out of 26). PBMCs were tested 
as control. Each dot represents a single MM case or PBMC isolate, and lines indicate the mean 
values (n = 26 MM cases; n = 8 PBMC isolates).   
(B-C) Western blot analysis of MM cells purified from newly diagnosed (naïve) and 
relapsed/refractory patients and treated with NSC12 for 12 hours; GAPDH was probed for loading 
control (n = 3 MM cases). GAPDH image for pts. 4 and 5 are the same in B and C since obtained 
from the same blot.  
(D) qPCR analysis for the expression levels of oxidative-stress induced genes in patient-derived 
MM cells treated with NSC12 6 M for 6 hours (n = 3 MM cases). 
(E) Immunofluorescence analysis and quantification of patient-derived MM cells treated with 
NSC12 6 M for 12 hours (n = 2 MM cases). Scale bar 20 m.  
(F) Cytofluorimetric analysis of patient-derived MM cells treated with NSC12 10 M for 12 hours 
in the presence or absence of Vitamin E (n = 3 MM cases).  
Data are mean ± SEM. #p < 0.001.  
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Figure 7. Resistance to Bortezomib does not affect the antitumor activity of FGF blockade.  
(A) MM cells purified from naïve or refractory/relapsed patients were treated with NSC12 10 M 
for 12 hours and cell death assessed by cytofluorimetric analysis (n = 26 MM cases).  
(B) Bortezomib-resistant (KMS-11/BTZ) or parental KMS-11 cells were treated with increasing 
doses of BTZ or NSC12 for 48 hours and assessed for viable cell counting by cytofluorimetric 
analysis.   
(C) Western blot analysis of KMS-11/BTZ cells treated with NSC12 6 M.  
(D) Cytofluorimetric analysis of mtROS production (MitoSox), mitochondrial membrane 
depolarization (TMRE) and apoptotic cell death in KMS-11/BTZ cells treated with NSC12 6 M. 
(E) Tumor growth (right panel) and tumor weight (left panel) of KMS-11/BTZ cells grafted s.c and 
orally treated (arrows) with NSC12 or vehicle (n = 5 mice/group).  
(F) qPCR analysis for the expression levels of TXNCD5 and PRDX3 genes in parental and BTZ-
resistant KMS-11 cells treated with NSC12 6 M.   
Data are mean ± SEM. In box and whiskers graphs, boxes extend from the 25th to the 75th 
percentiles, lines indicate the median values, and whiskers indicate the range of values.  
*p < 0.05, **p < 0.01, #p < 0.001. 
 
 







